Showing results (41-50 of 49) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Breast Cancer Research and Treatment|June 15, 2023
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cellsTaronish D Dubash, Aditya Bardia, Brian Chirn, et al.Analytical Chemistry|April 13, 2022
Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGSCeline Callens, Francois-Clement Bidard, Anaïs Curto-Taribo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2024
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 StudyPatrick Neven, Nicole Stahl, Maria Vidal, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2016
The Genomic Landscape of Male Breast CancersSalvatore Piscuoglio, Charlotte K Y Ng, Melissa P Murray, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2022
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD TrialFrancois-Clement Bidard, Virginia G Kaklamani, Patrick Neven, et al.Critical Reviews in Oncology/Hematology|June 8, 2025
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus reportFederica Miglietta, Maria Grazia Razeti, Aldo Caltavituro, et al.European Journal of Cancer (Oxford, England : 1990)|July 15, 2021
Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysisAndreas D Hartkopf, Sara Y Brucker, Florin-Andrei Taran, et al.JNCI Cancer Spectrum|April 28, 2020
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research DirectionsRyan J O Dowling, Joseph A Sparano, Pamela J Goodwin, et al.JNCI Cancer Spectrum|April 28, 2020
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical ConsiderationsRyan J O Dowling, Kevin Kalinsky, Daniel F Hayes, et al.Pageof 5